🔥🔥🔥 JOIN OUR STARTUP AMBASSADOR PROGRAM 🔥🔥🔥
    📣 Spread the news & get a PRO membership 3 months for FREE with all features🚀📈💵500 vouchers left • 3 months free
    Arkin Holdings logo

    Arkin Holdings

    Family Office · (Israel)

    Family Office
    Seed
    Series A
    Healthcare
    Cloud/SaaS

    Sign up free to access full profile and submit your pitch.

    About

    FAMILY HISTORY In 1961 Mr. Ziama Arkin founded Agis as the certified Israeli pharmaceutical importer for a number of foreign pharma companies. After the death of Mr. Ziama Arkin in 1972, his 19 year old son, Mori, took the lead, while he was serving in the IDF and completing a degree in Psychology. In 1994, Agis purchased Clay Park and gained with it, control over its first production facility. A new era of Agis drug development and production had begun. Under Mori Arkin, who remained the principal shareholder and chairman of the board, Agis (1983) Ltd. grew to become one of the biggest leaders in the dermatological generic space in the US. In 2005 Perrigo (PRGO) purchased Agis in an $818M transaction. Arkin Holdings is dedicated to empowering companies that create breakthrough pharma, biotech and medical device technologies. Our synergistic healthcare investments are dedicated to creating innovations that benefit humanity and enhance medical care. We offer extensive experience, with a track record of successful healthcare investments. Experts in the dynamic world of healthcare development, we provide the know-how and close accompaniment that helps our portfolio investments achieve substantial value and growth.

    Visit website ↗

    Investment Criteria

    Sign up free to see full investment criteria and submit your pitch.

    Min. Ticket Size
    $0
    Max. Ticket Size
    $1,000,000
    Min. Revenue (ARR)
    $250,000
    Investment Stage
    Seed
    Series A
    Series B
    Series C
    Series D
    Growth Capital
    PE/Buy-out
    Regions
    Middle East
    North America
    Northern Europe
    Western Europe
    AUM
    $2B

    Similar Investors

    We use cookies to enhance your experience. Read our Privacy Policy